Cognition impairment in schizophrenia patients with tardive dyskinesia: Association with plasma superoxide dismutase activity

Schizophrenia Research

Volumn 152, Issue 1, 2014, Pages 210-216

  Wu, Jing Qin ^a,b,c   Chen, Da Chun ^c   Tan, Yun Long ^c   Tan, Shu Ping ^c   Wang, Zhi Ren ^c   Xiu, Mei Hong ^c   Yang, Fu De ^c   Zhang, Xiang Yang ^c,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c PEKING UNIVERSITY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cognition; Oxidative stress; Schizophrenia; Superoxide dismutase; Tardive dyskinesia

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REPEATABLE BATTERY FOR THE ASSESSMENT OFNEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; DISEASE ASSOCIATION; FEMALE; PROTEIN BLOOD LEVEL;

COGNITION; OXIDATIVE STRESS; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE; TARDIVE DYSKINESIA;

ANALYSIS OF VARIANCE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SUPEROXIDE DISMUTASE;

EID: 84891629655     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.11.010     Document Type: Article

References (66)

1. Asevedo E., Gadelha A., Noto C., Mansur R.B., Zugman A., Belangero S.I., Berberian A.A., Scarpato B.S., Leclerc E., Teixeira A.L., Gama C.S., Bressan R.A., Brietzke E. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J. Psychiatr. Res. 2013, 47(10):1376-1382.
2. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35(3):878-893.
3. Buckman T.D., Kling A.S., Eiduson S., Sutphin M.S., Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol. Psychiatry 1987, 22(11):1349-1356.
4. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res. 1990, 31(1):1-14.
5. Byne W., White L., Parella M., Adams R., Harvey P.D., Davis K.L. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int. J. Geriatr. Psychiatry 1998, 13(7):473-479.
6. Chen da C., Xiu M.H., Liu H., Zhang B.S., Wang Y., Kosten T.R., Zhang X.Y. Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. J. Psychiatr. Res. 2010, 44(15):1111-1112.
7. Condray R., Yao J.K. Cognition, dopamine and bioactive lipids in schizophrenia. Front. Biosci. (Schol. Ed.) 2011, 3:298-330.
8. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50(4-5):279-289.
9. Davis E.J., Borde M., Sharma L.N. Tardive dyskinesia and type II schizophrenia. Br. J. Psychiatry 1992, 160:253-256.
10. Dickerson F., Boronow J.J., Stallings C., Origoni A.E., Cole S.K., Yolken R.H. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004, 129(1):45-53.
11. Fukui K., Onodera K., Shinkai T., Suzuki S., Urano S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Ann. N. Y. Acad. Sci. 2001, 928:168-175.
12. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(3):512-515.
13. Gold J.M., Egan M.F., Kirch D.G., Goldberg T.E., Daniel D.G., Bigelow L.B., Wyatt R.J. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol. Psychiatry 1991, 30(6):587-599.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology: PublicationADM76-388 1976, US Department of Health, Education, and Welfare.
15. Halari R., Mehrotra R., Sharma T., Ng V., Kumari V. Cognitive impairment but preservation of sexual dimorphism in cognitive abilities in chronic schizophrenia. Psychiatry Res. 2006, 141(2):129-139.
16. Han M., Huang X.F., Chen da C., Xiu M.H., Hui L., Liu H., Kosten T.R., Zhang X.Y. Gender differences in cognitive function of patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39(2):358-363.
17. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry 2004, 65(3):361-372.
18. Hu D., Serrano F., Oury T.D., Klann E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J. Neurosci. 2006, 26(15):3933-3941.
19. Jablensky A., Angelicheva D., Donohoe G.J., Cruickshank M., Azmanov D.N., Morris D.W., McRae A., Weickert C.S., Carter K.W., Chandler D., Alexandrov B., Usheva A., Morar B., Verbrugghe P.L., Filipovska A., Rackham O., Bishop A.R., Rasmussen K.O., Dragovic M., Cooper M., Phillips M., Badcock J., Bramon-Bosch E., Almeida O.P., Flicker L., Gill M., Corvin A., MacGregor S., Kalaydjieva L. Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia. Mol. Psychiatry 2012, 17(12):1328-1339.
20. Johnson A.W., Jaaro-Peled H., Shahani N., Sedlak T.W., Zoubovsky S., Burruss D., Emiliani F., Sawa A., Gallagher M. Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(30):12462-12467.
21. Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 2011, 10(2):187-198.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
23. King D.J., Wilson A., Cooper S.J., Waddington J.L. The clinical correlates of neurological soft signs in chronic schizophrenia. Br. J. Psychiatry 1991, 158:770-775.
24. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161(2 Suppl.):1-56.
25. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., Cynader M.S. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139(1-2):27-35.
26. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 1990, 28(6):535-539.
27. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17(1):47-62.
28. Massuda R., Pedrini M., Reckziegel R., Costanzi M., Ferrari P., Gubert C., Gama C.S. Elevated serum protein oxidative stress in siblings of patients with schizophrenia. Schizophr. Res. 2013, 147(2-3):398-399.
29. Mukerjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996, 19(1):19-26.
30. Nagai T., Yamada K., Kim H.C., Kim Y.S., Noda Y., Imura A., Nabeshima Y., Nabeshima T. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003, 17(1):50-52.
31. Nicolle M.M., Gonzalez J., Sugaya K., Baskerville K.A., Bryan D., Lund K., Gallagher M., McKinney M. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 2001, 107(3):415-431.
32. Olson I.R., Plotzker A., Ezzyat Y. The Enigmatic temporal pole: a review of findings on social and emotional processing. Brain 2007, 130(Pt 7):1718-1731.
33. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci. Lett. 2010, 479(3):317-320.
34. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol. Rev. 2009, 19(3):365-384.
35. Peet M., Laugharne J., Rangarajan N., Reynolds G.P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int. Clin. Psychopharmacol. 1993, 8(3):151-153.
36. Radak Z., Kumagai S., Taylor A.W., Naito H., Goto S. Effects of exercise on brain function: role of free radicals. Appl. Physiol. Nutr. Metab. 2007, 32(5):942-946.
37. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20(3):310-319.
38. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003, 121(2):109-122.
39. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr. Res. 2003, 62(3):205-212.
40. Sachdev P.S. The current status of tardive dyskinesia. Aust. N. Z. J. Psychiatry 2000, 34(3):355-369.
41. Sarro S., Pomarol-Clotet E., Canales-Rodriguez E.J., Salvador R., Gomar J.J., Ortiz-Gil J., Landin-Romero R., Vila-Rodriguez F., Blanch J., McKenna P.J. Structural brain changes associated with tardive dyskinesia in schizophrenia. Br. J. Psychiatry 2013, 203(1):51-57.
42. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 1982, 39(4):486-487.
43. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 2003, 26(1):25-40.
44. Struve F.A., Willner A.E. Cognitive dysfunction and tardive dyskinesia. Br. J. Psychiatry 1983, 143:597-600.
45. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry 1998, 155(9):1207-1213.
46. Waddington J.L., Youssef H.A. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am. J. Psychiatry 1986, 143(9):1162-1165.
47. Waddington J.L., Youssef H.A. Cognitive dysfunction in chronic schizophrenia followed prospectively over 10years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol. Med. 1996, 26(4):681-688.
48. Waddington J.L., Youssef H.A., Dolphin C., Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch. Gen. Psychiatry 1987, 44(10):907-912.
49. Waddington J.L., Youssef H.A., King D.J., Cooper S.J. Association of cognitive dysfunction, altered brain morphology, and release of developmental reflexes with tardive dyskinesia in schizophrenia and bipolar affective disorder. Schizophrenia: Scientific Progress 1989, 396-403. Oxford University Press, New York. C. Schulz, C.A. Tamminga (Eds.).
50. Waddington J.L., O'Callaghan E., Larkin C., Kinsella A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia?. Brain Cogn. 1993, 23(1):56-70.
51. Wegner J.T., Catalano F., Gibralter J., Kane J.M. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch. Gen. Psychiatry 1985, 42(9):860-865.
52. Wegner J.T., Kane J.M., Weinhold P., Woerner M., Kinon B., Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatry Res. 1985, 16(4):331-337.
53. Wisner K.M., Elvevag B., Gold J.M., Weinberger D.R., Dickinson D. A closer look at siblings of patients with schizophrenia: the association of depression history and sex with cognitive phenotypes. Schizophr. Res. 2011, 126(1-3):164-173.
54. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
55. Wu J.Q., Chen da C., Xiu M.H., Tan Y.L., Yang F.D., Kosten T.R., Zhang X.Y. Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 46:71-77.
56. Yamada K., Kanba S., Anamizu S., Ohnishi K., Ashikari I., Yagi G., Asai M. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol. Med. 1997, 27(5):1223-1225.
57. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox Signal. 2011, 15(7):2011-2035.
58. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid. Redox Signal. 2011, 15(7):1999-2002.
59. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 2000, 97(2-3):137-151.
60. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2003, 62(3):245-250.
61. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81(2-3):291-300.
62. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., Kosten T.A., Kosten T.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry 2007, 68(5):754-760.
63. Zhang B.H., Tan Y.L., Zhang W.F., Wang Z.R., Yang G.G., Shi C., Zhang X.Y., Zhou D.F. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: reliability and validity. Chin. Ment. Health J. 2009, 28:865-869.
64. Zhang X.Y., Chen da C., Xiu M.H., Yang F.D., Haile C.N., Kosten T.A., Kosten T.R. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J. Clin. Psychiatry 2012, 73(7):1025-1033.
65. Zhang X.Y., Chen D.C., Xiu M.H., Tang W., Zhang F., Liu L., Chen Y., Liu J., Yao J.K., Kosten T.A., Kosten T.R. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr. Res. 2012, 139(1-3):66-72.
66. Zhang X.Y., Chen da C., Xiu M.H., Tan Y.L., Yang F.D., Zhang L.Y., Haile C.N., Kosten T.R. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J. Psychiatr. Res. 2013, 47(8):1049-1053.